Evidence map›Paper›PMID 42105210›Full record

ArticleBioinformatics (Oxford, England)2026

Protein language model embeddings improve HIV drug resistance prediction: a comprehensive benchmark with attention-based interpretability.

Hayden Farquhar

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Hayden FarquharIndependent Researcher, Finley, New South Wales, Australia.ORCID 0009-0002-6226-440X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

motivationAccurate prediction of HIV drug resistance from viral sequences is critical for optimizing antiretroviral therapy. Traditional machine-learning approaches using binary mutation encoding achieve strong accuracy but may fail to capture epistatic interactions and structural features relevant to resistance mechanisms. Protein language models (PLMs) offer learned representations encoding evolutionary and structural information, but have not been systematically benchmarked for HIV resistance prediction across the modern antiretroviral drug set.

resultsWe evaluated ESM-2 (650 M parameters) with attention-weighted pooling for predicting resistance to 18 drugs across three classes (protease inhibitors, NRTIs, NNRTIs) on the Stanford HIVDB dataset (n = 6308 sequences). Attention-weighted ESM-2 embeddings significantly outperformed XGBoost baselines with binary mutation encoding (mean AUC 0.968 versus 0.955, P = .0017), with gains across 15 of 18 drugs and the largest improvements for drugs with complex resistance patterns. Attention weights showed 2.48-fold enrichment at known drug-resistance-mutation positions (P < .05 for 63% of drugs; NRTIs strongest at 4.20-fold). External validation on a 20% holdout showed minimal degradation (AUC 0.934). Benchmarking against ESM C 600M and ESM-1v confirmed performance is robust to PLM choice (mean AUC 0.942-0.946 across backbones). Performance was maintained across HIV-1 subtypes (B 0.924; B-divergent 0.900; non-B 0.884) and a temporal holdout (AUC 0.930). AVAILABILITY AND IMPLEMENTATION: Source code is available at https://github.com/hayden-farquhar/HIV-ESM-2 under an MIT license and archived at https://doi.org/10.5281/zenodo.19466629. Stanford HIVDB genotype-phenotype data are publicly available at https://hivdb.stanford.edu/.

Indexed as

Anti-HIV AgentsComputational BiologyDrug Resistance, ViralHIV-1HIV InfectionsHumansMachine LearningMutationAnti-HIV Agents

Identifiers

PMID42105210
PMCPMC13198382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.